Novartis, Pfizer, GSK seen as potential buyers of Serono

11/9/2005 | Wall Street Journal, The

Serono's multiple sclerosis drug Rebif, which had sales of more than $1 billion last year, may be the biggest attraction for potential buyers of Europe's largest biotech company. Serono confirmed it has hired Goldman Sachs to explore strategies but said a sale is not a certainty. The Wall Street Journal reports Novartis, Pfizer and GlaxoSmithKline have been in talks with Serono about a possible takeover, which could include a $15 billion price tag.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC